Cefadroxil monohydrate
Executive Summary
Bristol-Myers Squibb patent is valid, the International Trade Commission concludes in a final determination March 15. The commission determined that the valid patent rendered illegal the importation of the product by generic competitors Biocraft and Purepac. Cease and desist orders were issued against the generic companies prohibiting domestic marketing of the antibiotic; a limited exclusion order prohibiting importation was issued against foreign firms GEMA, Istituto Biochimico Italiano Industria Giovanni Lorenzini and Institut Biochimique. Bond for all the companies included in both orders has been set at 68% of the entered value of the imported articles during a 60-day Presidential review period. If the final determination is not rejected, the orders hold until the patent expires in 2002, or an appeal. The cease and desist orders corroborate temporary orders in place since Jan. 10 ("The Pink Sheet" Jan. 22, "In Brief").
|
Bristol-Myers Squibb patent is valid, the International Trade
Commission concludes in a final determination March 15. The
commission determined that the valid patent rendered illegal the
importation of the product by generic competitors Biocraft and
Purepac. Cease and desist orders were issued against the generic
companies prohibiting domestic marketing of the antibiotic; a
limited exclusion order prohibiting importation was issued against
foreign firms GEMA, Istituto Biochimico Italiano Industria Giovanni
Lorenzini and Institut Biochimique. Bond for all the companies
included in both orders has been set at 68% of the entered value of
the imported articles during a 60-day Presidential review period.
If the final determination is not rejected, the orders hold until
the patent expires in 2002, or an appeal. The cease and desist
orders corroborate temporary orders in place since Jan. 10 ("The
Pink Sheet" Jan. 22, "In Brief"). |